{"id":"phenylephrine-1-0-ketorolac-0-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or stinging"},{"rate":null,"effect":"Conjunctival blanching"},{"rate":null,"effect":"Rebound hyperemia"},{"rate":null,"effect":"Systemic absorption effects (tachycardia, hypertension)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Phenylephrine is an alpha-1 adrenergic agonist that causes vasoconstriction of conjunctival blood vessels, reducing ocular hyperemia and redness. Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin-mediated inflammation and pain. Together, they address both the vascular and inflammatory components of ocular irritation and redness.","oneSentence":"This combination ophthalmic drop uses phenylephrine to constrict blood vessels and reduce redness while ketorolac provides anti-inflammatory and analgesic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:07.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ocular redness and irritation associated with allergic conjunctivitis or post-operative inflammation"}]},"trialDetails":[{"nctId":"NCT06681688","phase":"PHASE1, PHASE2","title":"Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC","status":"RECRUITING","sponsor":"Inder Paul Singh, M.D.","startDate":"2024-07-10","conditions":"Cataract","enrollment":94},{"nctId":"NCT06539637","phase":"EARLY_PHASE1","title":"Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%","status":"RECRUITING","sponsor":"DHS Consulting","startDate":"2023-09-01","conditions":"Cataract","enrollment":20},{"nctId":"NCT04829799","phase":"PHASE4","title":"Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2022-02","conditions":"Pain Reduction","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Phenylephrine 1.0%/ Ketorolac 0.3%","genericName":"Phenylephrine 1.0%/ Ketorolac 0.3%","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination ophthalmic drop uses phenylephrine to constrict blood vessels and reduce redness while ketorolac provides anti-inflammatory and analgesic effects. Used for Ocular redness and irritation associated with allergic conjunctivitis or post-operative inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}